Compare Stocks: EPRX, PHVS, ZYME, and BCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$7.65 -1.7%	$8.79	$6.23 ▼ $11.22	$1.95B	0.55	5.48 million shs	2.75 million shs
EPRX Eupraxia Pharmaceuticals	$6.87 -9.5%	$7.60	$5.25 ▼ $9.32	$446.68M	0.83	1.01 million shs	348,796 shs
PHVS Pharvaris	$31.41 +2.4%	$33.98	$21.02 ▼ $43.25	$2.05B	-2.46	676,048 shs	621,705 shs
ZYME Zymeworks	$28.22 -0.8%	$27.12	$16.00 ▼ $31.34	$2.00B	1.17	1.36 million shs	1.12 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-1.80%	-10.21%	-18.09%	+8.05%
EPRX Eupraxia Pharmaceuticals	0.00%	+3.78%	-15.81%	+18.24%	+25.14%
PHVS Pharvaris	0.00%	+13.23%	-4.79%	-8.08%	+33.89%
ZYME Zymeworks	0.00%	+12.74%	+5.26%	+23.45%	+59.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$7.65 -1.7%	$8.79	$6.23 ▼ $11.22	$1.95B	0.55	5.48 million shs	2.75 million shs
EPRX Eupraxia Pharmaceuticals	$6.87 -9.5%	$7.60	$5.25 ▼ $9.32	$446.68M	0.83	1.01 million shs	348,796 shs
PHVS Pharvaris	$31.41 +2.4%	$33.98	$21.02 ▼ $43.25	$2.05B	-2.46	676,048 shs	621,705 shs
ZYME Zymeworks	$28.22 -0.8%	$27.12	$16.00 ▼ $31.34	$2.00B	1.17	1.36 million shs	1.12 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-1.80%	-10.21%	-18.09%	+8.05%
EPRX Eupraxia Pharmaceuticals	0.00%	+3.78%	-15.81%	+18.24%	+25.14%
PHVS Pharvaris	0.00%	+13.23%	-4.79%	-8.08%	+33.89%
ZYME Zymeworks	0.00%	+12.74%	+5.26%	+23.45%	+59.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.45	Hold	$19.44	154.18% Upside
EPRX Eupraxia Pharmaceuticals	2.90	Moderate Buy	$17.80	159.10% Upside
PHVS Pharvaris	2.87	Moderate Buy	$59.53	89.54% Upside
ZYME Zymeworks	2.79	Moderate Buy	$41.58	47.35% Upside

Current Analyst Ratings Breakdown

Latest EPRX, PHVS, ZYME, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	ZYME Zymeworks	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$52.00
10/23/2026	PHVS Pharvaris	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/23/2026	PHVS Pharvaris	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$44.00
10/20/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/15/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	PHVS Pharvaris	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ZYME Zymeworks	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $34.00
10/6/2026	PHVS Pharvaris	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$60.00
10/6/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$874.84M	2.23	$1.24 per share	6.18	($0.57) per share	-13.42
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
ZYME Zymeworks	$105.96M	18.90	N/A	N/A	$3.59 per share	7.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	10.63	N/A	-40.90%	-86.89%	66.37%	11/4/2026 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	27.94	N/A	-405.31%	-72.30%	-37.18%	11/9/2026 (Estimated)

Latest EPRX, PHVS, ZYME, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	PHVS Pharvaris	-$0.8187	N/A	N/A	N/A	$2.35 million	N/A
11/9/2026	Q3 2026	ZYME Zymeworks	$2.26	N/A	N/A	N/A	$227.38 million	N/A
11/4/2026	Q3 2026	BCRX BioCryst Pharmaceuticals	$0.0919	N/A	N/A	N/A	$165.67 million	N/A
11/3/2026	Q3 2026	EPRX Eupraxia Pharmaceuticals	-$0.26	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
PHVS Pharvaris	N/A	11.94	11.94
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
EPRX Eupraxia Pharmaceuticals	N/A
PHVS Pharvaris	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	3.80%
EPRX Eupraxia Pharmaceuticals	N/A
PHVS Pharvaris	11.84%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	435	255.54 million	245.83 million	Optionable
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
PHVS Pharvaris	148	65.41 million	57.66 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	Optionable

EPRX, PHVS, ZYME, and BCRX Headlines

Recent News About These Companies

Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026

October 24 at 7:20 AM | marketscreener.comM

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 24 at 2:30 AM | globenewswire.com

Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones

October 23 at 7:36 PM | finance.yahoo.com

Zymeworks signs Roche DLL3 deal, up to $813M

October 23 at 10:10 AM | ijr.comI

Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal

October 23 at 10:10 AM | msn.com

Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra

October 23 at 10:10 AM | fiercebiotech.comF

Roche pays $55 million upfront for Zymeworks’ DLL3 T cell engager ZW209

October 23 at 10:10 AM | thepharmaletter.comT

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

October 23 at 10:10 AM | pharmexec.comP

Zymeworks Inc. Enters Into An Exclusive Global License And Collaboration Agreement With F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. For ZW209, A Trispecific T Cell ...

October 23 at 10:10 AM | marketscreener.comM

Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug

October 23 at 10:10 AM | marketwatch.com

Zymeworks stock surges on $813M Roche licensing deal

October 23 at 10:10 AM | finance.yahoo.com

Zymeworks Enters Global Collaboration with Roche for ZW209 DLL3 T Cell Engager, Eligible for Up to $773 Million in Payments

October 23 at 6:11 AM | quiverquant.comQ

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

October 23 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NASDAQ:ZYME) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

October 20, 2026 | americanbankingnews.com

Zymeworks hires Pacira commercial exec Suzanne Monahan to run Yupelri business after Theravance deal

October 19, 2026 | thepharmaletter.comT

Zymeworks Inc. Announces Appointment of Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma, Effective October 19, 2026

October 19, 2026 | marketscreener.comM

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

October 19, 2026 | globenewswire.com

Assenagon Asset Management S.A. Buys 256,042 Shares of Zymeworks Inc. $ZYME

October 18, 2026 | marketbeat.com

Zymeworks Sets Q3 2026 Results Date and Ramps Up Investor Conference Presence

October 15, 2026 | tipranks.com

Zymeworks Announces Third Quarter 2026 Financial Results Date and Upcoming Investor Conference Participation

October 15, 2026 | quiverquant.comQ

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

October 15, 2026 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, PHVS, ZYME, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$7.65 -0.13 (-1.67%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$7.67 +0.02 (+0.26%)

As of 10/23/2026 07:30 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.87 -0.72 (-9.49%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$6.90 +0.03 (+0.42%)

As of 10/23/2026 07:30 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Pharvaris NASDAQ:PHVS

$31.41 +0.73 (+2.38%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$31.44 +0.02 (+0.08%)

As of 10/23/2026 07:30 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Zymeworks NASDAQ:ZYME

$28.22 -0.22 (-0.77%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$27.44 -0.78 (-2.75%)

As of 10/23/2026 07:57 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, PHVS, ZYME, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, PHVS, ZYME, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, PHVS, ZYME, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, PHVS, ZYME, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Eupraxia Pharmaceuticals NASDAQ:EPRX

Pharvaris NASDAQ:PHVS

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, PHVS, ZYME, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, PHVS, ZYME, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, PHVS, ZYME, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, PHVS, ZYME, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Eupraxia Pharmaceuticals NASDAQ:EPRX

Pharvaris NASDAQ:PHVS

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools